Replies to post #1432 on Synaptogenix Inc (SNPX)

[InTheTrenches]

SF:

That is good news!

Thanks for posting.

[SF Wolf]

Some obvious questions for NTRP investors regarding Dr. Alkon’s upcoming March 22nd Keynote presentation at the Sachs Associates 2nd Annual Neuroscience BioPartnering & Investment Forum:

--Was Dr. Alkon invited as this year’s Keynote speaker due to recent developments in Neurotrope’s Bryostatin Alzheimer study? (He was also the keynote at last year’s conference.)

-- In his comments will Dr. Alkon review Neurotrope’s AD Ph2b study? If so, will his comments discuss anecdotal results or possibly a more detailed examination of the study outcomes? (I would think that in three weeks time NTRP and Dr. Alkon will have un-blinded study results and be deep into statistical analysis of the data).


--Will Dr. Alkon seek Big Pharma investment partners? “The event is targeted at buy and sell side analysts from investment banks and funds and partnering executives from pharma.”